Drug intelligence / Profile preview

natural killer cell-derived extracellular vesicles

Development stage
Preclinical
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Intravenous, Intratumoral
01

Overview

Natural killer cell-derived extracellular vesicles (NKEVs) are nanosized, cell-free particles secreted by natural killer (NK) cells that function as mediators of intercellular communication and immune effector activity. These vesicles carry a cargo of cytotoxic proteins, including perforin and granzymes, as well as various nucleic acids and membrane markers (e.g., CD56) that allow them to target and induce apoptosis in malignant cells. NKEVs are being explored as an off-the-shelf immunotherapy for hematological malignancies, such as leukemia and lymphoma, and for inflammatory conditions like acute-on-chronic liver failure (ACLF), where they have been shown to alleviate CD8+ T cell exhaustion via the TGF-beta/Smad pathway. Compared to whole-cell therapies like CAR-NK, NKEVs offer potential advantages in terms of stability, lower immunogenicity, and reduced risk of cytokine release syndrome.

Other names
NKEVsNK-EVsNK cell-derived extracellular vesicles
02

Targets

GZMB (Granzyme B)PRF1 (Zinc finger protein 395)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on natural killer cell-derived extracellular vesicles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on natural killer cell-derived extracellular vesicles.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call